Eosinophilic Esophagitis: Prevalence, Diagnosis, and Treatment in Childhood and Adulthood.

IF 6.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL
André Hoerning, Jens-Oliver Steiß, Ahmed Madisch, Jan de Laffolie
{"title":"Eosinophilic Esophagitis: Prevalence, Diagnosis, and Treatment in Childhood and Adulthood.","authors":"André Hoerning, Jens-Oliver Steiß, Ahmed Madisch, Jan de Laffolie","doi":"10.3238/arztebl.m2025.0042","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Eosinophilic esophagitis is a chronic, Th2 immune-mediated disease of the esophagus characterized by eso - phageal dysfunction and predominant eosinophilic inflammation. Its prevalence and incidence have risen in recent years and now stand at 16.1 per 100 000 persons and 1.7 per 100 000 persons per year.</p><p><strong>Methods: </strong>This review is based on selected publications retrieved by a search in PubMed, Medline, and Google Scholar for clinical trials, reviews, and guidelines that were published between 2011 and 2024 in either English or German (search term, \"eosinophilic esophagitis\").</p><p><strong>Results: </strong>Eosinophilic esophagitis markedly impairs patients' quality of life; its diagnosis is often delayed. It can be treated with an appropriately altered diet, pharmacotherapy, and/or endoscopic intervention (\"diet, drugs, dilatation\"). Elimination diets with the omission of 2, 4, or 6 food groups lead to histological remission in 43%, 60%, and 79% of patients, respectively. An entirely amino acid-based diet leads to histological remission in over 90% of patients, but can only be performed for a limited time. Topical corticosteroids lead to histological remission in 60-87% of cases, proton-pump inhibitors in 30-50%, and dupilumab (anti-IL- 4Rα/IL-13Rα1) in 60-86%. These treatments differ widely in their side-effect profiles and in the restrictions they impose in everyday life, and their use must be considered individually for each patient. Because eosinophilic esophagitis is a chronic disease, remission maintenance therapy is needed over the long term.</p><p><strong>Conclusion: </strong>Eosinophilic esophagitis was first described three decades ago. Effective treatments are available, but questions remain concerning the longterm course of the disease, remission maintenance therapy, and non-invasive markers of disease activity, among others. Delays in diagnosis should be avoided. The appropriate treatment and long-term care of the affected patients are needed to assure them an optimal quality of life.</p>","PeriodicalId":11258,"journal":{"name":"Deutsches Arzteblatt international","volume":" Forthcoming","pages":"195-202"},"PeriodicalIF":6.5000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Deutsches Arzteblatt international","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3238/arztebl.m2025.0042","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Eosinophilic esophagitis is a chronic, Th2 immune-mediated disease of the esophagus characterized by eso - phageal dysfunction and predominant eosinophilic inflammation. Its prevalence and incidence have risen in recent years and now stand at 16.1 per 100 000 persons and 1.7 per 100 000 persons per year.

Methods: This review is based on selected publications retrieved by a search in PubMed, Medline, and Google Scholar for clinical trials, reviews, and guidelines that were published between 2011 and 2024 in either English or German (search term, "eosinophilic esophagitis").

Results: Eosinophilic esophagitis markedly impairs patients' quality of life; its diagnosis is often delayed. It can be treated with an appropriately altered diet, pharmacotherapy, and/or endoscopic intervention ("diet, drugs, dilatation"). Elimination diets with the omission of 2, 4, or 6 food groups lead to histological remission in 43%, 60%, and 79% of patients, respectively. An entirely amino acid-based diet leads to histological remission in over 90% of patients, but can only be performed for a limited time. Topical corticosteroids lead to histological remission in 60-87% of cases, proton-pump inhibitors in 30-50%, and dupilumab (anti-IL- 4Rα/IL-13Rα1) in 60-86%. These treatments differ widely in their side-effect profiles and in the restrictions they impose in everyday life, and their use must be considered individually for each patient. Because eosinophilic esophagitis is a chronic disease, remission maintenance therapy is needed over the long term.

Conclusion: Eosinophilic esophagitis was first described three decades ago. Effective treatments are available, but questions remain concerning the longterm course of the disease, remission maintenance therapy, and non-invasive markers of disease activity, among others. Delays in diagnosis should be avoided. The appropriate treatment and long-term care of the affected patients are needed to assure them an optimal quality of life.

嗜酸性粒细胞性食管炎:儿童和成人的患病率、诊断和治疗。
背景:嗜酸性粒细胞性食管炎是一种慢性、Th2免疫介导的食管疾病,以食管功能障碍和嗜酸性粒细胞性炎症为主要特征。其流行率和发病率近年来有所上升,目前分别为每10万人16.1例和每年每10万人1.7例。方法:本综述基于PubMed、Medline和谷歌Scholar检索到的2011年至2024年间发表的英文或德文临床试验、综述和指南(检索词为“嗜酸性食管炎”)。结果:嗜酸性粒细胞性食管炎明显影响患者的生活质量;它的诊断常常被延误。可以通过适当改变饮食、药物治疗和/或内镜干预(“饮食、药物、扩张”)来治疗。剔除2、4或6种食物组的消除饮食分别导致43%、60%和79%的患者组织学缓解。完全以氨基酸为基础的饮食导致90%以上的患者的组织学缓解,但只能在有限的时间内进行。局部皮质类固醇导致60-87%的病例组织学缓解,30-50%的质子泵抑制剂,60-86%的dupilumab(抗il - 4r α/IL-13Rα1)。这些治疗方法的副作用和在日常生活中施加的限制差别很大,必须针对每个患者单独考虑其使用。由于嗜酸性粒细胞性食管炎是一种慢性疾病,需要长期的缓解维持治疗。结论:嗜酸性粒细胞性食管炎在30年前首次被发现。有效的治疗方法是可用的,但关于疾病的长期病程、缓解维持治疗和疾病活动的非侵入性标志物等问题仍然存在。应避免延误诊断。需要对受影响的患者进行适当的治疗和长期护理,以确保他们获得最佳的生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Deutsches Arzteblatt international
Deutsches Arzteblatt international 医学-医学:内科
CiteScore
4.10
自引率
5.20%
发文量
306
审稿时长
4-8 weeks
期刊介绍: Deutsches Ärzteblatt International is a bilingual (German and English) weekly online journal that focuses on clinical medicine and public health. It serves as the official publication for both the German Medical Association and the National Association of Statutory Health Insurance Physicians. The journal is dedicated to publishing independent, peer-reviewed articles that cover a wide range of clinical medicine disciplines. It also features editorials and a dedicated section for scientific discussion, known as correspondence. The journal aims to provide valuable medical information to its international readership and offers insights into the German medical landscape. Since its launch in January 2008, Deutsches Ärzteblatt International has been recognized and included in several prestigious databases, which helps to ensure its content is accessible and credible to the global medical community. These databases include: Carelit CINAHL (Cumulative Index to Nursing and Allied Health Literature) Compendex DOAJ (Directory of Open Access Journals) EMBASE (Excerpta Medica database) EMNursing GEOBASE (Geoscience & Environmental Data) HINARI (Health InterNetwork Access to Research Initiative) Index Copernicus Medline (MEDLARS Online) Medpilot PsycINFO (Psychological Information Database) Science Citation Index Expanded Scopus By being indexed in these databases, Deutsches Ärzteblatt International's articles are made available to researchers, clinicians, and healthcare professionals worldwide, contributing to the global exchange of medical knowledge and research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信